09966 ALPHAMAB-B
- 2.350
- 0.0000.00%
ALPHAMAB-B News
Alphamab Oncology to Present the Latest Clinical Data of Anti-HER2 Bispecific ADC JSKN003 at the ESMO Congress 2024
The latest clinical research data for Kangning Jerry's HER2 bispecific ADC drug JSKN003 will be released at the 2024 ESMO Congress.
Suzhou, August 12, 2024 /PRNewswire/ -- Concordium Biopharma Co., Ltd. (Stock Code: 9966.HK) announced that the latest clinical data of HER2 bispecific antibody-conjugated drug (ADC) JSKN003 for the treatment of platinum-resistant ovarian cancer and advanced HER2-positive (IHC 3+) solid tumors will be presented in poster form at the 2024 European Society for Medical Oncology (ESMO) Congress. This year's ESMO Congress will be held in Barcelona, Spain from September 13-17, 2024. Topic: JSKN003 (a
Hang Seng Index: Benefiting from policy support, biotechnology stocks have seen three consecutive months of inflows.
The Hang Seng Index company stated that there are signs of improvement in the recent situation of biotechnology stocks, as well as benefitting from policy support and three consecutive months of inflow of funds.
On August 15th, Conjugate Pharmaceuticals-B (09966.HK) held a board of directors meeting to consider and approve mid-term performance.
On August 2, Glorious Sun announced that Koninklijke Pharmaceutics (09966.HK) will hold a board of directors meeting on Thursday, August 15, 2024 to consider and approve the company's and its subsidiaries' interim performances for the six months ended June 30, 2024, as well as to handle other matters.
ALPHAMAB-B: DATE OF BOARD MEETING
HKEX Live | Concord Medical Bio-B (09966) fell more than 7%, company's overseas expansion hindered due to the failure of core product's clinical trial in foreign markets.
Zhixun Finance APP has learned that Koning Jieyi Pharmaceuticals-B (09966) fell more than 7%. As of the press release, it fell 7.23% to HKD 2.18, with a turnover of HKD 7.6199 million. Recently, Koning Jieyi Pharmaceuticals' partner TRACON in the United States announced that due to the failure of Enwolimumab to achieve the primary endpoint in clinical trials, further development will be terminated. This means that Koning Jieyi's only commercialized product, Enwolimumab's first indication, has temporarily failed overseas. Previously in 2019, Koning Jieyi Pharmaceuticals reached a collaboration agreement with TRACON in the United States, which was responsible for Tracon company.
Express News | Alphamab Oncology - Collaboration With Arrivent for Research, Development and Commercialization of ADC Products
Hong Kong Stock Market Movement| Concorde Pharmacy-B (09966) soared by 19%, clinical research on the treatment of late-stage solid tumors showed good tolerance
Zhixun Finance learned from the APP that Kangning Jerry Pharmaceuticals B (09966) surged 19%. As of press time, it rose 19.08% to HK$3.02, with a turnover of HK$87.057 million. On the news side, Kangning Jerry Pharmaceuticals recently announced that the Phase I clinical study data of its new HER2-targeting bispecific antibody conjugate (ADC) JSKN003 for HER2-expressing solid tumors in China will be first released at the 2024 ASCO Annual Meeting. The research conclusion shows that JSKN003 has good tolerability and in patients with advanced/metastatic solid tumors who have previously undergone multiple lines of systemic treatment.
China's clinical research data for the Kangningjeri HER2 bispecific antibody drug JSKN003 was first presented at the 2024 ASCO Annual Meeting.
The Phase I clinical study results of JSKN003-102 were reported at this year's ASCO Annual Meeting. JSKN003 has good tolerability and controllable safety in advanced/metastatic solid tumor patients receiving previous multi-line system treatments, and has shown encouraging anti-tumor activity during the dose escalation period. Suzhou, June 3, 2024 / PRNewswire/ -- Concorde Jerry Biopharmaceuticals (stock code: 9966.HK) announced the Phase I clinical research data (study number: JSKN003) of HER2 bispecific antibody drug JSKN003 for the treatment of HER2-expressing solid tumors in China.
Alphamab Presents Results of Phase 1/2 China Trial for Tumor Drug in US Oncology Meeting
Corning Jerry Pharmaceutical-B (09966.HK): The latest findings of the JSKN003 Phase I/II clinical study on advanced solid tumors presented at the 2024 ASCO Annual Meeting
On June 3, GLONGHUI | Corning Jerry Pharmaceutical-B (09966.HK) announced that the results of the JSKN003 phase I/ II clinical study (study number: JSKN003-102) (“JSKN003-102”) for patients with advanced solid tumors were announced during the 2024 ASCO Annual Meeting poster presentation (abstract number: 3031; poster number: 176), and the results of this study were also published on the company's website.
Changes in Hong Kong stocks | Corning Jerry Pharmaceutical-B (09966) continues to fall 6%, KN046-303 clinical trial failed
Corning Jerry Pharmaceutical-B (09966) continued to drop 6%, and the stock closed down nearly 45% yesterday. As of press release, it decreased by 6.08% to HK$2.47, with a turnover of HK$396.06 million.
Alphamab's Phase 3 Trial for Pancreatic Cancer Treatment Fails to Reach Preset Statistical Endpoint; Shares Plunge 38%
Changes in Hong Kong stocks | Corning Jerry Pharmaceutical-B (09966) opened nearly 15% lower, and the overall survival results of the KN046-303 trial did not reach the intended end point
Corning Jerry Pharmaceutical-B (09966) opened nearly 15% lower in early trading. As of press release, it decreased by 14.92% to HK$4.05, with a turnover of HK$1,846,800.
Corning Jerry Pharmaceutical-B (09966): The KN046-303 trial has reached the pre-set number of deaths
Corning Jerry Pharmaceutical-B (09966) announced the latest developments relating to KN046-303, KN046...
Corning Jerry Pharmaceutical-B (09966.HK) issued 80,000 shares due to the exercise of share options
On May 28, GLONGHUI | Corning Jerry Pharmaceutical-B (09966.HK) announced that on May 28, 2024, 80,000 shares will be issued in accordance with the pre-initial public sale share option plan 2 adopted on March 29, 2019.
Corning Jerry completes first patient administration in phase I clinical study of HER3/TROP2 dual antibody ADC drug JSKN016
SUZHOU, May 22, 2024/PRNewswire/ -- Corning Jerry Biopharmaceuticals (stock code: 9966.HK) announced that the Phase I clinical study (study number: JSKN016-101) of the HER3/TROP2 dual-antibody ADC drug JSKN016 in patients with advanced malignant solid tumors in China has completed its first patient administration. TROP2 (Trophoblast cell surface antigen 2, human trophoblast cell surface antigen 2) is widely expressed in solid tumors, and its upregulation can promote tumor growth
Corning Jerry Pharmaceutical-B (09966): Phase I clinical trial of JSKN016 to treat advanced malignant solid tumors completed first patient administration
Corning Jerry Pharmaceutical-B (09966) announced that JSKN016 (a human epidermal growth factor independently developed by the company...
Alphamab Oncology's (HKG:9966) 28% Share Price Surge Not Quite Adding Up
Corning Jerry will first announce Chinese clinical study data on JSKN003 treatment of HER2-expressing solid tumors at the 2024 ASCO Annual Meeting
SUZHOU, May 6, 2024/PRNewswire/ -- Corning Jerry Biopharmaceuticals (stock code: 9966.HK) announced that the company will first announce the Chinese clinical study data (study number: JSKN003-102) of the HER2 double antagonist conjugate drug JSKN003 to treat HER2-expressing solid tumors at the 2024 American Society of Clinical Oncology (ASCO) annual meeting. This year's ASCO Annual Meeting will be held in Chicago, USA from May 31 to June 4, 2024, local time. Topic: Safety and pharmacokinetics of JSKN003 in patients with advanced solid tumors
Analysis
Price Target
No Data
